Q4 Tuesday 30 Jan 08:00, CC 09:00 CET
We are looking for Ossur to report Q4 sales of USD 217.7m (+15% reported growth), some 5% above company-collected Consensus at USD 207.3m. We are inline with consensus on organic growth (~6%), which leaves our higher estimate driven by lower-quality M&A and FX assumptions. We are looking for EBITDA pre-items of USD 44.3m, +6% vs. consensus, likely due to the higher top-line. We assume a modest slowing of growth in the key Prosthetics business of 8% organically (12% in Q3), which still assumes healthy market share gains.
